Page last updated: 2024-11-06

coomassie brilliant blue

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID6324599
CHEMBL ID4173394
MeSH IDM0045838

Synonyms (32)

Synonym
c47h48n3nao7s2
6104-58-1
coomassie brilliant blue g
c.i. acid blue 90
brilliant blue g
brilliant blue g, pure
coomassie brilliant blue
page blue g 90, for microscopy
cbb g-250
B3193
AKOS015902421
BP-30127
AKOS025310853
HB0716
coomassie brilliant blue g (cbbg)
brilliant blue g, dye content ~60 % by elemental analysis
brillant blue g
brilliant blue g, ultrapure
brilliant blue g, 250, for microscopy
bril-lant blue g
coomassie brilliant blue g-250 [for electrophoresis]
sodium 3-(((4-((e)-(4-(4-ethoxyphenylamino)phenyl)((e)-4-(ethyl(3-sulfonatobenzyl)iminio)-2-methylcyclohexa-2,5-dienylidene)methyl)-3-methylphenyl)(ethyl)amino)methyl)benzenesulfonate
DB15594
RWVGQQGBQSJDQV-UHFFFAOYSA-M
bdbm50277548
sodium 3-(((4-((4-((4-ethoxyphenyl)amino)phenyl)(4-(ethyl(3-sulfonatobenzyl)iminio)-2-methylcyclohexa-2,5-dien-1-ylidene)methyl)-3-methylphenyl)(ethyl)amino)methyl)benzenesulfonate
CHEMBL4173394 ,
bleu brillant g
azul brillante g
azul brilhante g
blu brillante g
bbg;brilliant blue g-250

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"All dyes demonstrated relatively safe viability profiles in both cell lines at surgically relevant concentrations and times."( Comparison of the in vitro safety of intraocular dyes using two retinal cell lines: a focus on brilliant blue G and indocyanine green.
Gonder, J; Hutnik, C; Liu, H; Proulx, A; Yuen, D, 2009
)
0.35
"Gel destaining following Coomassie Brilliant Blue (CBB) staining involves the use of toxic reagents."( Environmentally safe removal/disposal of Coomassie Brilliant Blue from gel destain and used gel stain.
Dorri, Y; Kurien, BT, 2010
)
0.36
" We compared the in vitro toxicity of IfCG, BBG, and BPB with ICG on the retinal pigment epithelial cells and retinal ganglion cells at various concentrations to optimize the safe dose and duration of exposure."( Comparative in vitro safety analysis of dyes for chromovitrectomy: indocyanine green, brilliant blue green, bromophenol blue, and infracyanine green.
Balaiya, S; Brar, VS; Chalam, KV; Murthy, RK, 2011
)
0.37
" Infracyanine green, BBG, and BPB were significantly less toxic on the 2 cell lines at exposure times <15 minutes."( Comparative in vitro safety analysis of dyes for chromovitrectomy: indocyanine green, brilliant blue green, bromophenol blue, and infracyanine green.
Balaiya, S; Brar, VS; Chalam, KV; Murthy, RK, 2011
)
0.37
"Newer vital dyes, IfCG, BBG, and BPB, are significantly less toxic on retinal ganglion cells and retinal pigment epithelial cells' cell lines when compared with ICG."( Comparative in vitro safety analysis of dyes for chromovitrectomy: indocyanine green, brilliant blue green, bromophenol blue, and infracyanine green.
Balaiya, S; Brar, VS; Chalam, KV; Murthy, RK, 2011
)
0.37
" In contrast, BBG and TA appear safe after subretinal injection."( Toxicity profiles of subretinal indocyanine green, Brilliant Blue G, and triamcinolone acetonide: a comparative study.
Ejstrup, R; Heegaard, S; Kiilgaard, JF; la Cour, M, 2012
)
0.38
"Combinations of trypan blue (TB), Brilliant Blue G (BBG) and polyethyleneglycol had been shown before to be less toxic to ARPE retinal pigment epithelial cells than TB alone."( Brilliant Blue G as protective agent against trypan blue toxicity in human retinal pigment epithelial cells in vitro.
Awad, D; Bartok, M; Gabel, D; Mohr, A; Schrader, I; Sudumbrekar, N, 2013
)
0.39
"075 % and higher was toxic to the cells already after 30 min incubation."( Brilliant Blue G as protective agent against trypan blue toxicity in human retinal pigment epithelial cells in vitro.
Awad, D; Bartok, M; Gabel, D; Mohr, A; Schrader, I; Sudumbrekar, N, 2013
)
0.39
" Adverse retinal staining was not noted and the final visual acuity showed no difference with multiple staining."( Brilliant Blue G double staining enhances successful internal limiting membrane peeling with minimal adverse effect by low cellular permeability into live cells.
Asato, R; Enaida, H; Hisatomi, T; Ikeda, Y; Ishibashi, T; Murakami, Y; Notomi, S; Oishi, S; Sakamoto, T; Tachibana, T; Yamashita, T, 2015
)
0.42
" To test this, a nontoxic triphenylmethane dye, Brilliant Blue G (BBG), which has been reported to modulate Aβ aggregation and neurotoxicity, was investigated using mouse primary cortical neuronal cultures treated with photoinduced cross-linked toxic Aβ40 oligomers as well as soluble Aβ40 and Aβ42 peptides."( Oligomeric Amyloid-β Toxicity Can Be Inhibited by Blocking Its Cellular Binding in Cortical Neuronal Cultures with Addition of the Triphenylmethane Dye Brilliant Blue G.
Cappai, R; Ciccotosto, GD; Jana, MK, 2016
)
0.43
" However, BBG dye, though considered safe and nontoxic, can also occasionally lead to macular toxicity."( Brilliant Blue G toxicity in macular hole surgeries: A report on combined phototoxicity and dye-induced macular damage.
Chhablani, J; Dogra, A; Pappuru, RR; Parameswarappa, DC; Sahoo, NK; Soni, A; Tyagi, M, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" Solubilizing curcumin with Tween 80 would be a useful alternative to increase curcumin bioavailability in clinical studies."( Heat/Pressure Treatment with Detergents Significantly Increases Curcumin Solubility and Stability: Its Use as an Environment-Friendly Protein Gel Stain.
Kurien, BT; Payne, A; Scofield, RH; Thomas, R, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" Therefore, the present study aimed to trial a modified injection regime using more frequent dosing of BBG to improve outcomes in this model of GVHD."( P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model.
Adhikary, SR; Casolin, S; Cuthbertson, P; Geraghty, NJ; Sluyter, R; Watson, D, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (669)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990169 (25.26)18.7374
1990's98 (14.65)18.2507
2000's95 (14.20)29.6817
2010's262 (39.16)24.3611
2020's45 (6.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (2.04%)5.53%
Reviews13 (1.89%)6.00%
Case Studies9 (1.31%)4.05%
Observational2 (0.29%)0.25%
Other649 (94.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]